Liver cirrhosis: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PPAR 0
• GLP-1 0
• SGLT2 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• YAP 0
• AMPK 0
• TP53 0
• PNPLA3 1
• IL-17 0
• JAK 0
• MAPK 0
• NLRP3 0
• SIRT1 0
• TLR4 0
• STING 0
• CTNNB1 0
• HIF-1 0
• IL-6 0
• PD-1 0
• PD-L1 0
• CXCR4 0
• DPP-4 0
• JNK 0
• NRF2 0
• APOE 0
• BCL-2 0
• ERK 0
• EZH2 0
• FGFR 0
• HMGB1 0
• HSP90 0
• IL-23 0
• MDM2 0
• METTL3 0
• PCSK9 0
• PDGFR 0
• PSMA 1
• PTEN 0
• TNF 0
• VEGF 0
• ABL1 0
• ALK 0
• CD19 0
• CD20 0
• CD38 0
• COX-2 0
• FAK 0
• FTO 0
• IDH 0
• LAG-3 0
• MMP-9 0
• MYC 0
• NPM1 0
• PARP 0
• PKD1 0
• PKM2 0
• TERT 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Tracking the Intestinal Permeation and Circulation Effects of Environmental MicroPlastics (TRACE-MP)

  Queen Mary University of London· London, Egyesült Királyság· EU contribution 292 073 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Izrael· EU contribution 150 000 EUR· until 2028. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Scalable target identification for metabolic liver disease (3DMASH)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 950 000 EUR· until 2030. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Promoting RObust Systems biology on Patients and Experimental models with obesity-driven liveR cancer (PROSPER)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 183 601 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Function of Cholangiocytes in chronic liver diseases (FunChol)

  Charite - Universitaetsmedizin Berlin· Berlin, Németország· EU contribution 2 499 289 EUR· until 2029. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 13 854 593 EUR· until 2030. febr.· 13 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients (ARTEMIS)

  Matical Innovation Sl· Madrid, Spanyolország· EU contribution 9 365 095 EUR· until 2027. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Liver Electronic Offering Platform with Artificial intelligence-based Devices (LEOPARD)

  Assistance Publique Hopitaux de Paris· Paris, Franciaország· EU contribution 6 320 857 EUR· until 2028. okt.· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D (D-SOLVE)

  Medizinische Hochschule Hannover· Hannover, Németország· EU contribution 6 754 010 EUR· until 2027. szept.· 5 countries

• European Commission (Horizon 2020) · ERC-ADG

  Targeted strategies for prevention and treatment of fibrosis-associated liver cancer (FIBCAN)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 2 430 000 EUR· until 2028. jún.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 10 running projects, newest first. Listed amounts together: 43,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 17
• Organoids 16
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 3
• Gene Expression Profiling 77
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 58
• Metabolomics 53
• Mass Spectrometry 9
• Flow Cytometry 9
• Immunohistochemistry 36
• Liquid Biopsy 7
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 4
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 131
• Machine Learning 88
• Deep Learning 30
• Cohort Studies 178
• Genome-Wide Association Study 34

• Intrahepatic Tissue-Resident CD8+ T-Cell Programmes Associate With Fibrosis and Local Immune Remodelling in Autoimmune Hepatitis.

  Liver Int, 2026. nov.

• CD11c+ T-Bet+ B Cell Expansion Reveals a Distinct Pathogenic Signature in Autoimmune Liver Diseases.

  Liver Int, 2026. aug.

• Extracellular Vesicles Reflect Thrombo-Inflammatory, Endothelial and Tissue-Remodelling Changes in Cirrhosis.

  Liver Int, 2026. júl.

• A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.

  Aliment Pharmacol Ther, 2026. júl.

• LC3-Associated Phagocytosis in Hepatitis C Virus-Induced Fibrosis.

  Microbiol Immunol, 2026. ápr.

• Curcumin protects against liver fibrosis by attenuating infiltration of Gr1hi monocytes through inhibition of monocyte chemoattractant protein-1.

  Discov Med, 2016. jún.

• Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.

  Lab Invest, 2012. aug.

• Vitamin D3 modulates T lymphocyte responses in hepatitis C virus-infected liver transplant recipients.

  Dig Liver Dis, 2011. szept.

• [Preliminary research on the mechanism of apoptosis hepatic stellate cells induced by zedoary turmeric oil].

  Zhonghua Gan Zang Bing Za Zhi, 2009. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.